Biotech Values

[dav1234]

Bristol-Myers Squibb's (BMY +1.3%) oral three-drug combo for hepatitis C cured 94% of patients with 12 or 24 weeks of treatment in a Phase II trial. The company now hopes to start Phase III trials by late 2013. Bristol's positive results add to those of AbbVie (ABBV +2.9%), although Gilead (GILD -0.7%) appears to be ahead in the race to market with an oral hepatitis C drug, having already filed an FDA NDA for its sofosbuvir treatment.
http://m.seekingalpha.com/news-article/6303151-high-rates-of-svr-demonstrated-in-phase-ii-study-with-investigational-triple-daa-regimen-of-daclatasvir-asunaprevir-and-bms-791325-in-treatment-nave-patients-with-genotype-1-chronic-hepatitis-c-infection